The positive correlation found between elevated expression of the GATA2 gene in clinical metastatic prostate cancers and poor patient prognosis (Fig. 2A–C), as also reported by others [47], indicates that the findings are clinically relevant, and that elevated expression of GATA2 is associated with malignant progression of prostate cancer. This evidence concerns the gene GATA2 and prostate cancer.